SAFETY AND EFFECTIVENESS IN REDUCED DOSE OF OMALIZUMAB FOR CHRONIC IDIOPATIC URTICARIA

M. ALONSO MORENO, M. SORIANO MARTINEZ, B. FERNANDEZ RUBIO, M. MEJIAS TRUEBA.

1HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO, PHARMACY, SEVILLE, SPAIN

BACKGROUND AND IMPORTANCE

Omalizumab (anti IgE) → Chronic Idiopathic Urticaria (CIU)

150 MG (REDUCED DOSE)

300 MG

AIM AND OBJECTIVES

Safety and effectiveness of omalizumab in both doses for the treatment of CIU

MATERIAL AND METHODS

Observational, descriptive and retrospective study of omalizumab prescribed for adult patients in CIU from January 2015 to September 2019 in a third level hospital.

Variables collected: sex, age, service (allergy or dermatology), previous treatments, initiating dosing, dose change, clinical variable Urticaria Activity Score 7 (UAS7), suspension of treatment and adverse events (AE)

RESULTS

<table>
<thead>
<tr>
<th>INITIATING DOSING</th>
<th>300 mg monthly</th>
<th>Intensified dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=49</td>
<td>N=7</td>
<td></td>
</tr>
<tr>
<td>N=3</td>
<td>N=22</td>
<td></td>
</tr>
<tr>
<td>150 mg monthly</td>
<td>Decreased to 150 mg monthly</td>
<td></td>
</tr>
</tbody>
</table>

67.31% women
median age of 50.5 years

65.38% allergy
34.62% dermatology

N=52

All patients previously received antihistamines, montelukast and cyclosporine.

CONCLUSIONS AND RELEVANCE

There is a high percentage of patients in our center with a dose of 300 mg monthly of omalizumab for CIU, however a reduced dose (150 mg monthly) has also proved to be equally effective and safe, even stopping the treatment for improvement of CIU which would be also economic impact.

AE → n=2 alopecia and asthenia; and weight gain